Cargando…

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

BACKGROUND: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) is secreted from adipocytes in association with catecholamine-induced lipolysis, and elevated serum FABP4 level is associated with obesity, insulin resistance and atherosclerosis. Secreted FABP4 as a novel adipokine leads to insulin resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuhashi, Masato, Matsumoto, Megumi, Hiramitsu, Shinya, Omori, Akina, Tanaka, Marenao, Moniwa, Norihito, Yoshida, Hideaki, Ishii, Junnichi, Miura, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849662/ https://www.ncbi.nlm.nih.gov/pubmed/27124282 http://dx.doi.org/10.1371/journal.pone.0154482

Ejemplares similares

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters
por: Furuhashi, Masato, et al.
Publicado: (2016)

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages
por: Furuhashi, Masato, et al.
Publicado: (2017)

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study
por: Saito, Norie, et al.
Publicado: (2021)

Increased LDL-cholesterol level is associated with deterioration of renal function in males
por: Osanami, Arata, et al.
Publicado: (2022)

A Case of Crescentic Glomerulonephritis Complicated with Hypocomplementemic Urticarial Vasculitis Syndrome and ANCA-Associated Vasculitis
por: Tanaka, Marenao, et al.
Publicado: (2017)

Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
por: Furuhashi, Masato, et al.
Publicado: (2019)

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria
por: Tanaka, Marenao, et al.
Publicado: (2020)

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells
por: Yamamoto, Tokunori, et al.
Publicado: (2016)

Differential regulation of hypoxanthine and xanthine by obesity in a general population
por: Furuhashi, Masato, et al.
Publicado: (2020)

Low urine pH predicts new onset of diabetes mellitus during a 10‐year period in men: BOREAS‐DM1 study
por: Higashiura, Yukimura, et al.
Publicado: (2020)

High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects
por: Higashiura, Yukimura, et al.
Publicado: (2021)

Differential Phenotypes in Perivascular Adipose Tissue Surrounding the Internal Thoracic Artery and Diseased Coronary Artery
por: Numaguchi, Ryosuke, et al.
Publicado: (2019)

Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects
por: Takahashi, Satoko, et al.
Publicado: (2021)

Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10‐Year Period in Both Male and Female Subjects
por: Higashiura, Yukimura, et al.
Publicado: (2021)

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases
por: Furuhashi, Masato, et al.
Publicado: (2015)

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury
por: Fuseya, Takahiro, et al.
Publicado: (2017)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
por: Furuhashi, Masato, et al.
Publicado: (2011)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
por: Furuhashi, Masato, et al.
Publicado: (2020)

Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation
por: Ota, Hideki, et al.
Publicado: (2012)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Reply to the comments of Naharci et al. on “Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals”
por: Tanaka, Marenao, et al.
Publicado: (2022)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population
por: Ishimura, Shutaro, et al.
Publicado: (2013)

Urinary Excretion of Fatty Acid-Binding Protein 4 is Associated with Albuminuria and Renal Dysfunction
por: Okazaki, Yusuke, et al.
Publicado: (2014)

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023)

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
por: Jojima, Teruo, et al.
Publicado: (2019)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Shiba, Kumiko, et al.
Publicado: (2018)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

SGLT2 Inhibitors—A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling
por: Yagi, Takashi, et al.
Publicado: (2022)

Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population
por: Fuseya, Takahiro, et al.
Publicado: (2014)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Lipid Chaperones and Metabolic Inflammation
por: Furuhashi, Masato, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Reduction of endoplasmic reticulum stress inhibits neointima formation after vascular injury
por: Ishimura, Shutaro, et al.
Publicado: (2014)

Rationale and Design of the CANONICAL Study　― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―
por: Kasama, Shu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_90d5i38ljcfmflie068riaqp1m